Medical Properties Trust Inc acquires and develops net-leased healthcare facilities... Show more
Medical Properties Trust, Inc. is a self-advised real estate investment trust (REIT) founded in 2003 and headquartered in Birmingham, Alabama. The company acquires, develops, and leases net-leased hospital facilities, operating under long-term leases in which tenants generally cover most property-level expenses. As of September 30, 2026, MPT owned 365 facilities with approximately 37,000 licensed beds across nine countries and three continents, making it one of the world's largest owners of hospital real estate. Investors follow the stock closely because its diversified healthcare portfolio, tenant credit quality, and balance-sheet management directly influence distributable cash flow and dividend sustainability.
MPT's share price has been under sustained pressure. In the 30 days through early November 2026, the stock declined approximately 39%, falling from a closing level of about $3.27 in early October to roughly $1.99. The downturn broadens over the quarter: from roughly $4.59 in early August 2026, shares have fallen about 57%. The trend has been consistently negative, with the steepest single-session losses occurring immediately after the company's third-quarter earnings release and a subsequent analyst downgrade.
The most recent leg lower was triggered by MPT's third-quarter 2026 results, reported on October 29. The company posted net income of $202.1 million, or $0.34 per share, compared with a net loss of $77.5 million a year earlier, and revenue of $250.1 million. However, normalized funds from operations came in at $63.8 million, or $0.11 per share, below the prior-year figure of $0.13 and short of consensus. Management attributed a two-cent-per-share drag to tenant HSA, which did not pay its September rent amid ongoing billing and collections challenges.
The following day, RBC Capital analyst Michael Carroll downgraded the stock to Underperform from Sector Perform and cut the price target to $2.00 from $4.50, citing persistent tenant issues and a tight liquidity position. The downgrade compounded selling pressure, and shares fell sharply in heavy volume. Elevated short interest, reported at roughly 33.5% of the float in mid-October, further magnified the move. Offsetting some of the negative sentiment, Maxim Group reiterated a Buy rating, though the broader analyst consensus remained a Moderate Sell.
The quarterly decline reflects a longer-running narrative around tenant credit quality and balance-sheet execution. Throughout 2026, scrutiny of HSA — which assumed several former Steward Health Care facilities — has weighed on sentiment, including a short-seller report in March that flagged tenant health and liquidity concerns. MPT has responded with a sizable restructuring program: during the third quarter it completed roughly $680 million in asset sales and finalized a private offering of approximately $2.4 billion in secured notes used to repay near-term debt. The company also restructured its Priory lease at a roughly 18% rent reduction and recorded a $24 million impairment tied to Colombian assets. While these steps extended debt maturities and improved near-term liquidity, investors have remained focused on whether recurring cash flows can stabilize across the tenant base.
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading strategies. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary widely in strategy, holding timeframe, and performance metrics, giving traders a view into how data-driven systems approach different market conditions. Reviewing this section can help investors understand the signals and patterns that automated systems are monitoring across equities, sectors, and broader market dynamics.
Investors should monitor several factors in the months ahead. The most important is whether HSA resumes rent payments and whether Ovation Healthcare's operational turnaround improves collections, as management has indicated. Progress on refinancing the remaining $665 million of 2027 notes will also be closely watched, along with any further asset sales and their impact on the portfolio's cash-generating capacity. Dividend coverage and the payout ratio remain key areas of scrutiny, given the $0.09 per-share quarterly dividend. Finally, tenant performance across the broader portfolio, interest-rate trends affecting REIT valuations, and any additional analyst rating changes will continue to shape sentiment toward the stock.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 42 cases where MPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 74%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MPT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.240) is normal, around the industry mean (3.134). MPT has a moderately low P/E Ratio (-36.200) as compared to the industry average of (30.791). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). MPT's Dividend Yield (0.199) is considerably higher than the industry average of (0.050). P/S Ratio (1.994) is also within normal values, averaging (6.013).
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. MPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PublishingBooksMagazines